If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.95    0.285 (17.12%)
Bid:
1.70
Ask:
2.20
Spread: 0.50 (29.412%)
Market Cap: £320.00k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Settlement and CVA

30 Aug 2022 18:19

RNS Number : 6596X
Iconic Labs PLC
30 August 2022
 

For immediate release

ICONIC LABS PLC - IN ADMINISTRATION

Settlement of Disputes and Company Voluntary Arrangement

 

The Joint Administrators provide the following update on the administration, settlement of disputes and convening of a General Meeting:

Disputes with D sefton & Greencastle MediA

A Settlement Agreement has been entered into between the Company, Greencastle Media, Arch Capital Partners LLP, Mr D Sefton and the European High Growth Opportunities Securitization Fund. As a result, all litigation proceedings have been dismissed, and all claims, counter claims, including defamation claims, among the parties, have been waived or will be waived upon the CVA being approved.

 

A separate announcement has been issued relating to the retraction of claims made against David Sefton and the former directors of Iconic Labs PLC.

 

COMPANY VOLUNTRAY ARRANGEMENT PROPOSALS

Company Voluntary Arrangement ("CVA") Proposals have been finalised and are being sent out to all creditors and shareholders, together with Notices of Meetings of creditors and shareholders to consider the CVA which to be held on 22 September 2022, at 10.30 am and 2.00pm respectively. The General Meeting of Shareholders will include a Resolution to approve the CVA will be held at the offices of KWM Europe LLP, 9th Floor, 24 Monument Street, London, EC3R 8AJ. The meeting of shareholders will, if the CVA is passed, consider, in addition to a resolution to approve the CVA, resolutions to authorise the directors of the Company to allot shares and to disapply statutory pre-emption rights. These resolutions relating to the issuance of shares by the Company will be crucial to the Company's ability to raise future finance, including from the European High Growth Opportunities Securitization Fund as part of the "future funding" as described below.

A Form of Proxy must be completed, signed and received by Company's registrar, SLC Registrars, in accordance with the shareholders' circular.

 

FUTURE FUNDING

Subject to the CVA being approved and other resolutions being passed by shareholders at the General Meeting, the European High Growth Opportunities Securitization Fund have agreed to provide funding for the CVA and general working capital purposes, under existing and new facilities, subject to certain conditions precedent.

 

RE-LISTING OF SHARES

If the CVA is approved, the Board will enter into discussions with the Financial Conduct Authority with a view to the Company's suspension of shares being lifted. The Company's annual accounts for the year ended 30 June 2021 have been prepared and once audited will be published along with interim accounts to 31 December 2021.

 

ADMINISTRATION

If the CVA is approved, it is anticipated that the Administration will be brought to an end as soon as is practically possible.

 

 

30 August 2022

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDAFMSEESELA
Date   Source Headline
29th Apr 201910:14 amRNSTR1 Align Research
26th Apr 201911:05 amRNSHolding(s) in Company
26th Apr 201911:00 amRNSHolding(s) in Company
25th Apr 201910:30 amRNSUpdate on Option
23rd Apr 201911:30 amRNSHolding(s) in Company
17th Apr 201910:05 amRNSHolding(s) in Company
17th Apr 201910:00 amRNSHolding(s) in Company
16th Apr 201912:45 pmRNSHolding(s) in Company
12th Apr 201911:35 amRNSDirector's Interest
12th Apr 201911:30 amRNSHolding(s) in Company
8th Apr 201910:10 amRNSHolding(s) in Company
5th Apr 201912:15 pmRNSHolding(s) in Company
5th Apr 201912:10 pmRNSHolding(s) in Company
3rd Apr 20195:37 pmRNSHolding(s) in Company
2nd Apr 201910:15 amRNSUpdate
21st Mar 20195:02 pmRNSHolding(s) in Company
21st Mar 20195:01 pmRNSUpdate
21st Mar 20195:00 pmRNSHolding(s) in Company
21st Mar 20197:00 amRNSOne2One Investor Forum
19th Mar 20191:42 pmRNSHolding(s) in Company
19th Mar 20191:41 pmRNSHolding(s) in Company
18th Mar 20192:05 pmRNSSecond Price Monitoring Extn
18th Mar 20192:00 pmRNSPrice Monitoring Extension
18th Mar 201911:45 amRNSHolding(s) in Company
18th Mar 20199:05 amRNSSecond Price Monitoring Extn
18th Mar 20199:00 amRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSNew Media Business Created
14th Mar 201910:47 amRNSHolding(s) in Company
14th Mar 201910:46 amRNSUpdate
14th Mar 201910:45 amRNSHolding(s) in Company
12th Mar 20197:00 amRNSHolding(s) in Company
11th Mar 20198:48 amRNSHolding(s) in Company
8th Mar 20194:48 pmRNSHolding(s) in Company
8th Mar 20194:47 pmRNSUpdate
8th Mar 20194:46 pmRNSHolding(s) in Company
8th Mar 20194:45 pmRNSHolding(s) in Company
7th Mar 20192:05 pmRNSSecond Price Monitoring Extn
7th Mar 20192:00 pmRNSPrice Monitoring Extension
7th Mar 201911:00 amRNSPrice Monitoring Extension
6th Mar 20194:03 pmRNSUpdate
6th Mar 20192:00 pmRNSPrice Monitoring Extension
5th Mar 201911:05 amRNSSecond Price Monitoring Extn
5th Mar 201911:00 amRNSPrice Monitoring Extension
28th Feb 20192:20 pmRNSHolding(s) in Company
26th Feb 20195:44 pmRNSHolding(s) in Company
25th Feb 20198:12 amRNSDirectorate Change
22nd Feb 20195:50 pmRNSPublication of Prospectus
20th Feb 20194:06 pmRNSHolding(s) in Company
1st Feb 201912:35 pmRNSHolding(s) in Company
24th Jan 20193:37 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.